Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | HTR3A | P46098 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | HTR2C | P28335 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | CASP6 | P55212 | 1/20 | 0.71 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL1048 | 0.93 | KCNH2 (0.64) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Fumaric Acid SCHEMBL1049 | 0.93 | KCNH2 (0.64) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| SCHEMBL3321223 | 0.87 | KCNH2 (0.54) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| SCHEMBL1214 | 0.85 | KCNH2 (0.70) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL631 | 0.84 | KCNH2 (1.00) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL29377019 | 0.84 | KCNH2 (1.00) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL29387635 | 0.83 | CASP6 (1.00) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL806 | 0.83 | CASP6 (1.00) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| Alosetron SCHEMBL635233 | 0.82 | KCNH2 (0.96) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C | |
| SCHEMBL702 | 0.82 | KCNH2 (0.78) | KCNH2HTR3ACYP1A2CYP3A4ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5530008-A | USEFUL FOR TREATING ANXIETY DISORDER AND AGORAPHOBIA | SANDOZ LTD. (CH) | 1996-06-25 | — | — | US | claimed |
| US-5360800-A | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | GLAXO GROUP LIMITED (GB) | 1994-11-01 | — | — | US | claimed |
| EP-0306323-B1 | Lactam derivatives | GLAXO GROUP LTD (GB) | 1994-09-21 | — | — | EP | claimed |
| EP-0422154-B1 | THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS | SANDOZ AG (AT) | 1993-12-01 | — | — | EP | claimed |
| EP-0422154-A1 | THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS. | SANDOZ AG (AT) | 1991-04-17 | — | — | EP | claimed |
| WO-1990012569-A1 | THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS | SANDOZ AG (CH) | 1990-11-01 | — | — | WO | claimed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | claimed |
| US-5530008-A | USEFUL FOR TREATING ANXIETY DISORDER AND AGORAPHOBIA | SANDOZ LTD. (CH) | 1996-06-25 | — | — | US | disclosed |
| US-5360800-A | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | GLAXO GROUP LIMITED (GB) | 1994-11-01 | — | — | US | disclosed |
| EP-0306323-B1 | Lactam derivatives | GLAXO GROUP LTD (GB) | 1994-09-21 | — | — | EP | disclosed |
| EP-0422154-B1 | THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS | SANDOZ AG (AT) | 1993-12-01 | — | — | EP | disclosed |
| US-5229407-A | Administering to humans or animals for treatment of cognitive disorders | GLAXO GROUP LIMITED (GB) | 1993-07-20 | — | — | US | disclosed |
| US-5225407-A | Cognition activators | GLAXO GROUP LIMITED (GB) | 1993-07-06 | — | — | US | disclosed |
| EP-0450757-A2 | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood | GLAXO GROUP LIMITED (GB) | 1991-10-09 | — | — | EP | disclosed |
| EP-0422154-A1 | THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS. | SANDOZ AG (AT) | 1991-04-17 | — | — | EP | disclosed |
| WO-1990012569-A1 | THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS | SANDOZ AG (CH) | 1990-11-01 | — | — | WO | disclosed |
| EP-0357415-A2 | Use of serotonin antagonists in the treatment of cognitive disorders | GLAXO GROUP LIMITED (GB) | 1990-03-07 | — | — | EP | disclosed |
| EP-0357416-A2 | Use of serotonin antagonists in the treatment of drug addiction | GLAXO GROUP LIMITED (GB) | 1990-03-07 | — | — | EP | disclosed |
| EP-0357414-A2 | Use of serotonin antagonists in the treatment of depression | GLAXO GROUP LIMITED (GB) | 1990-03-07 | — | — | EP | disclosed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |